Please assess the completion status of the following clinical trial:

Trial Title: An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Has completed Study NS-0100-01, including all procedures required at Study Termination (Day 28/Visit 7) without major protocol deviations~2. Is male, or female and, if female, meets all of the following criteria:~   * Not breastfeeding~  * Post-menopausal or negative pregnancy test result (human chorionic gonadotropin, beta subunit \[β-hCG\]) at Screening (Visit 1) (not required for hysterectomized females)~  * If of childbearing potential (including perimenopausal women who have had a menstrual period within one year) and sexually active, must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods \[male condom with spermicide, with or without cervical cap or diaphragm\], implants, injectables, oral contraceptives \[must have been using for at least the last 3 months\], some intrauterine contraceptive devices, tubal ligation, or a vasectomized partner) during the entire duration of the study.~3. Is able to read, understand, and sign the informed consent forms (ICF) and if applicable, an authorization to use and disclose protected health information form (consistent with health insurance portability and accountability act of 1996 \[HIPAA\] legislation), communicate with the investigator, and understand and comply with protocol requirements.~Exclusion Criteria:~Subjects who meet any of the following criteria will be excluded from the study.~1. Is undesirable as a study participant as judged by the investigator (e.g., exhibited poor compliance during Study NS-0100-01)~2. Is expected to require treatment, or if currently on a stable dose, changes to their regimen of the following medications:~   * Lipid-lowering agents~  * Anti-hypertensive medications~  * Thyroid replacement therapy~  * Non-steroidal anti-inflammatory agents~3. Is expected to require or undergo treatment with any of the following medications:~   * Antidiabetes medications (with the exception of study medication \[i.e., metformin\])~  * Oral or parenteral steroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Metformin (Type: EXPERIMENTAL): 3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
- Mid Metformin (Type: EXPERIMENTAL): 3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
- High Metformin (Type: EXPERIMENTAL): 3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
- Metformin Monotherapy (Type: ACTIVE_COMPARATOR): 3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete